Low
₹1,736.20
High
₹1,827.50
| Previous Close | ₹1,751.10 |
|---|---|
| Day's Range | ₹1,736.20 - ₹1,827.50 |
| Open | ₹1,778.90 |
| 52 Week Range | ₹570.75 - ₹1,899.00 |
| Volume | 4,70,413 |
| Market Cap | ₹0.03 |
| Previous Close | ₹1,753.80 |
|---|---|
| Day's Range | ₹1,737.40 - ₹1,824.85 |
| Open | ₹1,773.85 |
| 52 Week Range | ₹571.00 - ₹1,896.15 |
| Volume | 17,643 |
| Market Cap | ₹0.03 |
| Trade Value ( ₹ in Lacs) | 8,362.93 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.09 |
| Price/Earning (TTM) | 100.73 |
| TTM EPS (₹) | 17.41 |
| P/E Ratio | 51.69 |
| Book Value(₹) | 21.63 |
| PAT Margin (%) | 6.52 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 29.22 |
| Trade Value ( ₹ in Lacs) | 313.79 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.09 |
| Price/Earning (TTM) | 100.73 |
| TTM EPS (₹) | 17.41 |
| P/E Ratio | 51.69 |
| Book Value(₹) | 21.63 |
| PAT Margin (%) | 6.52 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 29.22 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 2780.26 | 10738.43 |
| Expenses | N/A | N/A |
| PBT | 474.36 | 2232.8 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 351.52 | 1675.37 |
| Founded | 1999 |
|---|---|
| Managing Director | Pratibha Pilgaonkar |
| NSE Symbol | RUBICON |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,40,397.93 | 1,835.50 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,48,664.42 | 9,367.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,82,738.23 | 4,804.25 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,26,102.74 | 8,770.25 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,22,899.37 | 706.60 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,15,012.19 | 1,153.00 | 835.50 - 835.50 |
| Cipla Ltd. | 1,10,793.75 | 1,371.45 | 1,165.70 - 1,165.70 |
| Laurus Labs Ltd. | 1,05,644.55 | 1,955.25 | 823.10 - 823.10 |
| Max Healthcare Institute Ltd. | 1,02,684.23 | 1,055.00 | 903.00 - 903.00 |
| Aurobindo Pharma Ltd. | 99,828.06 | 1,735.00 | 1,066.80 - 1,066.80 |
No Records Found
In continuation of intimation dated September 5, 2026, regarding Notice of the 32nd Annual General Meeting and the Annual Report (AR) for FY 2025-26 of the Family Care Hospital, Family Care Hospitals has informed that a revised version of the Annual Report has been uploaded to the Company’s website. The company has informed that the revision in the AR are only relating to the correction of certain minor typographical / formatting issues and that there are no substantive changes being undertaken to the contents of the AR. The Notice of the 32nd Annual general Meeting and the Annual Report are also being uploaded on the website of the Company at www.familycarehospitals.com.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Rubicon Research Ltd. is ₹1,751.10 as of 2026-09-18.
The market capitalisation of Rubicon Research Ltd. is ₹29,030.99 as of 2026-09-18.
The 1-year return of Rubicon Research Ltd. is % as of .
The P/E ratio of Rubicon Research Ltd. is 51.69 as of 2026-09-19.
The 52-week high and low of Rubicon Research Ltd. are ₹1,899.00 and ₹570.75, respectively, as of 2026-09-18.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.